跳至主要内容
临床试验/PACTR201507001154522
PACTR201507001154522尚未招募Unknown

202090 (EBOLA Z CHAD3-004)

GlaxosSmithKline (GSK)0 个研究点目标入组 600 人开始时间: 2015年6月1日最近更新:
适应症

试验速览

阶段
Unknown
状态
尚未招募
发起方
入组人数
600

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
1 Year(s) 至 17 Year(s)(—)
性别
All

入选标准

  • Subjects parent(s)/ legally acceptable representative(s) (LAR[s]) who, in the opinion of the Investigator, can and will comply with the requirements of the protocol (e.g., availability for Diary Card completion, return for follow-up visits, availability for clinical follow-up throughout the study period).
  • ¿Written/ thumb printed informed consent obtained from the subject¿ parent(s)/ LAR(s) prior to performing any study specific procedure. In addition, written/ thumb printed informed assent should be obtained if appropriate (from all subjects aged 13 to 17 years and from younger subjects as per local requirements).
  • ¿A male or female child aged 1 to 17 years inclusive at the time of Screening.
  • (Amended 06 May 2015.)
  • ¿Subjects with a negative RDT test for Malaria within 30 days prior to randomisation into the study.
  • Subjects with a positive RDT test for Malaria who completed antimalarial treatment at least 5 days prior to randomisation into the study.
  • (Amended 06 May 2015.)
  • ¿Healthy subjects as per Investigator judgement, as established by medical history, clinical examination and haematology/ biochemistry laboratory parameters screening before entering into the study.
  • ¿Female subjects of non-childbearing potential may be enrolled in the study.
  • Non-childbearing potential is defined as pre-menarche or ovariectomy.
  • Please refer to the glossary of terms for the definition of menarche.
  • ¿Female subjects of childbearing potential may be enrolled in the study, if the subject:
  • has practiced adequate contraception for 30 days prior to the Day 0 visit, and
  • has a negative pregnancy test at the Day 0 visit, and has agreed to continue adequate contraception until 30 days after the Month 6 visit. Please refer to the glossary of terms for the definition of adequate contraception

排除标准

  • Child in care.
  • Please refer to the glossary of terms for the definition of child in care.
  • (Amended 06 May 2015.)
  • ¿Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine during the period starting 30 days before the Day 0 visit, or planned use during the study period.
  • ¿Previous vaccination with an investigational EBOV or Marburg vaccine, or previous vaccination with a chimpanzee adenoviral vectored investigational vaccine.
  • ¿Known prior EBOV or SUDV disease.
  • ¿Travel to country affected by the EBOV epidemic or direct contact with person with EVD within 21 days prior to the Day 0 visit.
  • ¿History of any reaction or hypersensitivity (such as anaphylaxis, urticaria [hives], respiratory difficulty, angioedema, or abdominal pain) likely to be exacerbated by any component of the study vaccine.
  • ¿Planned administration/ administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after each vaccination visit.
  • ¿Acute or chronic illness determined by medical history, clinical examination and laboratory screening tests including, but not limited to:
  • Clinically significant immunosuppressive or immunodeficient condition (e.g., clinical acquired immune deficiency syndrome [AIDS]).
  • Major congenital defects.
  • Malnutrition (defined as weight for age Z-score less than -3, or other clinical signs of malnutrition).
  • Any clinically significant haematological or biochemical laboratory abnormality (see APPENDIX C for acceptable limits for eligibility determination).
  • ¿Pregnant female.
  • ¿Any condition that in the Investigator¿s opinion may potentially compromise subject safety or interfere with subject assessment or compliance.
  • (Amended 06 May 2015.)

研究者

发起方
GlaxosSmithKline (GSK)

相似试验